Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
6,099
result(s) for
"Neal, David"
Sort by:
How to draw manga mecha
Mecha is a popular branch of manga that deals with robots and other machines. Readers will be able to draw their own mecha creations by following clear, step-by-step instructions.
Book
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
In men with prostate cancer on PSA screening, radical treatments led to half the incidence of metastasis and local progression as active monitoring without affecting disease-specific or overall survival.
Journal Article
How to draw fantasy manga
Wizards, monsters, and dragons are common sights in the pages of fantasy manga. Readers will be able to draw these fantasy creatures and many more by following clear instructions designed for young artists of all skill levels.
Book
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
In the ProtecT trial, over 1600 men with PSA-detected localized prostate cancer were assigned to active monitoring, prostatectomy, or radiotherapy. Although more patients assigned to active monitoring had disease progression, overall survival was similar in the three groups.
The management of clinically localized prostate cancer that is detected on the basis of prostate-specific antigen (PSA) levels remains controversial. In the United States alone, an estimated 180,890 cases will be diagnosed in 2016, and 26,120 men will die from the disease.
1
The widespread use of PSA testing has resulted in a dramatic increase in the diagnosis and treatment of prostate cancer, but many men do not benefit from intervention because the disease is either indolent or disseminated at diagnosis. Prostate cancer often progresses slowly, and many men die of competing causes. In addition, interventions for prostate cancer can have . . .
Journal Article
How to draw dramatic manga
Handsome suitors, magical shopkeepers, and guardian angels are just some of the characters used to create dramatic manga stories. They are also just some of the characters readers learn to draw as they follow simple, step-by-step instructions.
Book
The habitual consumer
Consumers sometimes act like creatures of habit, automatically repeating past behavior with little regard to current goals and valued outcomes. To explain this phenomenon, we show that habits are a specific form of automaticity in which responses are directly cued by the contexts (e.g., locations, preceding actions) that consistently covaried with past performance. Habits are prepotent responses that are quick to activate in memory over alternatives and that have a slow-to-modify memory trace. In daily life, the tendency to act on habits is compounded by everyday demands, including time pressures, distraction, and self-control depletion. However, habits are not immune to deliberative processes. Habits are learned largely as people pursue goals in daily life, and habits are broken through the strategic deployment of effortful self-control. Also, habits influence the post hoc inferences that people make about their behavior.
Journal Article
How to draw action manga
How can you create the illusion of movement in a drawing? What are simple action poses young artists can draw on their own? Readers discover the answers to these questions and many more about the world of action manga as they draw characters as diverse as heroic boys and cyborg assassins.
Book
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
The choice of treatment for PSA-detected, localized prostate cancer is influenced by effects of the interventions on quality of life. In the ProtecT trial, patterns of side-effect severity, improvement, and decline in urinary, sexual, and bowel function differed among the treatments.
As reported in a companion article in the
Journal,
the U.K. National Institute for Health Research–supported Prostate Testing for Cancer and Treatment (ProtecT) trial has shown no significant difference in prostate-cancer–specific mortality or all-cause mortality among men with prostate cancer detected by prostate-specific antigen (PSA) testing who were randomly assigned to radical prostatectomy, active monitoring (a surveillance strategy), or radical conformal radiotherapy with neoadjuvant hormonal therapy, at a median of 10 years of follow-up; however, the ProtecT trial has shown higher rates of metastases and disease progression among men in the active-monitoring group than among men in the radical-treatment groups. . . .
Journal Article
Violent ends : a novel in seventeen points of view
Relates how one boy--who had friends, enjoyed reading, playing saxophone in the band, and had never been in trouble before--became a monster capable of entering his high school with a loaded gun and firing on his classmates, as told from the viewpoints of several victims. Each perspective is written by a different writer of young adult fiction.
Book
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
Prostate cancer represents a substantial clinical challenge because it is difficult to predict outcome and advanced disease is often fatal. We sequenced the whole genomes of 112 primary and metastatic prostate cancer samples. From joint analysis of these cancers with those from previous studies (930 cancers in total), we found evidence for 22 previously unidentified putative driver genes harboring coding mutations, as well as evidence for
NEAT1
and
FOXA1
acting as drivers through noncoding mutations. Through the temporal dissection of aberrations, we identified driver mutations specifically associated with steps in the progression of prostate cancer, establishing, for example, loss of
CHD1
and
BRCA2
as early events in cancer development of
ETS
fusion-negative cancers. Computational chemogenomic (canSAR) analysis of prostate cancer mutations identified 11 targets of approved drugs, 7 targets of investigational drugs, and 62 targets of compounds that may be active and should be considered candidates for future clinical trials.
Joint analysis of new and previously published sequencing data for primary and metastatic prostate cancers identifies new candidate driver mutations and provides insights into disease progression and potential drug targets.
Journal Article